WHO
REGULATORY UPDATE
1st Invitation to Manufacturers of Therapeutics for Sickle Cell Disease to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit (PQT)
Published: 9/28/2026Detected: 8/13/2026
Summary preview
Launches the first WHO PQT invitation for manufacturers to submit an Expression of Interest (EOI) for evaluation of hydroxyurea products for the treatment of sickle cell disease, with emphasis on child-appropriate, safe…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
pediatrics
hematology
clinical
quality
#WHO prequalification
#PQT
#expression of interest (EOI)
#hydroxyurea
#sickle cell disease
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices10/2/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available10/2/2026
- PQ Webinar: Launch of WHO Prequalification of Medical Devices10/2/2026
- New EUL listing10/2/2026
- Prequalification of In Vitro Diagnostics: Scope Expansion10/2/2026